70,662 DexCom, Inc. $DXCM Shares Purchased by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 13.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 609,412 shares of the medical device company’s stock after buying an additional 70,662 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al owned about 0.16% of DexCom worth $52,586,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Interchange Capital Partners LLC lifted its stake in shares of DexCom by 9.7% in the third quarter. Interchange Capital Partners LLC now owns 4,865 shares of the medical device company’s stock worth $421,000 after acquiring an additional 429 shares during the period. Financial Network Wealth Advisors LLC increased its position in DexCom by 154.5% during the 3rd quarter. Financial Network Wealth Advisors LLC now owns 588 shares of the medical device company’s stock valued at $51,000 after purchasing an additional 357 shares during the period. China Universal Asset Management Co. Ltd. increased its position in DexCom by 15.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,316 shares of the medical device company’s stock valued at $1,414,000 after purchasing an additional 2,197 shares during the period. BOKF NA raised its holdings in DexCom by 78.7% during the 3rd quarter. BOKF NA now owns 19,202 shares of the medical device company’s stock worth $1,657,000 after purchasing an additional 8,454 shares during the last quarter. Finally, Pinnacle Wealth Planning Services Inc. raised its holdings in DexCom by 89.4% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 572 shares of the medical device company’s stock worth $49,000 after purchasing an additional 270 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Trending Headlines about DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly results exceeded expectations. DexCom reported revenue of approximately $1.34 billion, up 11.1% year over year, and adjusted earnings of $0.73 per share, surpassing analyst estimates of $0.68. U.S. revenue grew 14%, supported by demand for its continuous glucose monitoring products and adoption of the G7 15 Day system. DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
• Positive Sentiment: Margins improved materially. Non-GAAP operating margin reached 25.3%, while gross profit increased 18.2% and operating profit rose 34.9% year over year. The stronger earnings profile likely reinforced confidence in DexCom’s growth and cost management. DexCom Q3 2026 Earnings
• Positive Sentiment: Full-year outlook was raised. Management increased the midpoint of its 2026 revenue forecast to a range of $5.20 billion to $5.25 billion and lifted operating-margin and adjusted-EBITDA-margin guidance.
• Positive Sentiment: Shareholder returns received a boost. DexCom authorized a new $1.0 billion share buyback, which could support earnings per share and signal management’s confidence in cash generation. DexCom Announces $1 Billion Equity Buyback
• Positive Sentiment: Analyst sentiment improved. Barclays raised its price target from $115 to $120 while maintaining an “overweight” rating, citing potential upside following the results and improved outlook.
• Neutral Sentiment: Institutional ownership data showed substantial buying by several funds, including Invesco and Arrowstreet, but also significant reductions by other investors. This suggests mixed positioning rather than a clear institutional consensus.
• Negative Sentiment: Insider selling remains a cautionary signal. DexCom insiders reported 26 open-market sales and no purchases over the past six months. A recent sale by EVP Sadie Stern was made under a pre-arranged Rule 10b5-1 plan, reducing its predictive value, but the broader pattern may limit enthusiasm among some investors.

Insider Activity

In other news, Director Nicholas Augustinos sold 6,539 shares of DexCom stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $84.04, for a total value of $549,537.56. Following the completion of the sale, the director owned 29,293 shares in the company, valued at $2,461,783.72. The trade was a 18.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Brown sold 1,700 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $85.48, for a total transaction of $145,316.00. Following the transaction, the executive vice president owned 98,185 shares in the company, valued at $8,392,853.80. The trade was a 1.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 24,822 shares of company stock worth $2,090,833. Company insiders own 0.28% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on DXCM shares. Stifel Nicolaus set a $95.00 price target on shares of DexCom and gave the stock a “buy” rating in a research report on Friday, July 31st. Wells Fargo & Company upped their price objective on shares of DexCom from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. BTIG Research increased their price objective on shares of DexCom from $90.00 to $96.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Mizuho set a $100.00 target price on shares of DexCom in a research note on Tuesday, October 13th. Finally, Citigroup restated a “buy” rating and issued a $88.00 target price (up from $84.00) on shares of DexCom in a report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $92.91.

DexCom Stock Up 3.0%

Shares of DexCom stock opened at $82.29 on Friday. DexCom, Inc. has a one year low of $54.11 and a one year high of $92.59. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. The stock’s 50-day moving average is $85.82 and its 200 day moving average is $74.65. The firm has a market cap of $31.05 billion, a price-to-earnings ratio of 32.27, a PEG ratio of 1.34 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.68 by $0.05. The business had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.33 billion. DexCom had a return on equity of 36.96% and a net margin of 19.42%. The firm’s revenue was up 11.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.61 earnings per share. Equities research analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current year.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.